ArticleCommunications biology2026
Organoid Modeling and Single-Cell Profiling Reveal Smooth Muscle Cell Migration in Moyamoya Disease.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07505576 (Serum Anti-alpha-actinin Antibodies as an Early Biomarker for Histological Activity in Lupus Nephritis and Its Correlation With Other Conventional Serological Markers), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serum Anti-alpha-actinin Antibodies as an Early Biomarker for Histological Activity in Lupus Nephritis and Its Correlation With Other Conventional Serological Markers
Who cites it
2 citing papers in PubMed.
- Article
- HGSNAT alleviates oxygen-glucose deprivation- induced endothelial injury by suppressing ER stress: implications for Moyamoya disease.Frontiers in molecular neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Moyamoya disease (MMD) is a cerebrovascular disorder characterized by progressive intracranial arterial stenosis, which can lead to ischemic or hemorrhagic stroke. However, its pathogenesis remains poorly understood, limiting advances in the diagnosis and treatment of MMD. We perform data-independent acquisition (DIA) proteomics on serum samples from 40 MMD patients and 20 healthy controls, followed by ELISA validation of an additional 45 cohort. Vascular organoids are generated from induced pluripotent stem cells (iPSCs) derived from the peripheral blood, and analyzed using histological staining, transcriptomics, and single-cell RNA sequencing (scRNA-seq). Histological examination of the temporal superficial artery (STA) in MMD patients reveals abnormal accumulation of vascular smooth muscle cells (VSMCs). DIA proteomics identify significant upregulation of TUBA4A and TUBB4B in MMD serum. In vitro assays demonstrate that these tubulin proteins promoted VSMC proliferation, migration, and contractile-to-synthetic phenotypic switching through the GJA1/PI3K/AKT/KLF4 signaling pathway. Single-cell RNA sequencing of MMD vascular organoids shows an increased proportion of synthetic VSMCs with upregulated TUBA4A and TUBB4B expression. Our findings suggest that overexpression of TUBA4A and TUBB4B contributes to pathological vascular remodeling in MMD through the GJA1/PI3K/AKT/KLF4 pathway, as well as therapeutic targets for intervention in MMD vascular remodeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.